By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Upper respiratory combinations > Chlorpheniramine and hydrocodone > Chlorpheniramine / Hydrocodone Dosage
Upper respiratory combinations
https://themeditary.com/dosage-information/chlorpheniramine-hydrocodone-dosage-11066.html

Chlorpheniramine / Hydrocodone Dosage

Drug Detail:Chlorpheniramine and hydrocodone (Chlorpheniramine and hydrocodone [ klor-fen-ir-a-meen-and-hye-droe-koe-done ])

Drug Class: Upper respiratory combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Cold Symptoms

Immediate-release (IR): 5 mL orally every 4 to 6 hours as needed
Maximum dose: 20 mL in 24 hours

  • Each 5 mL of IR oral solution contains hydrocodone bitartrate 5 mg with chlorpheniramine maleate 4 mg

Extended-release (ER): One dose orally every 12 hours
Maximum dose: 2 doses in 24 hours
  • A dose equals 1 ER capsule or 5 mL ER suspension; each dose provides hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 8 mg chlorpheniramine maleate

Comments:
  • Oral solution and suspension must be measured with an accurate milliliter measuring device; do not use a household teaspoon.

Use: For the symptomatic relief of cough and upper respiratory symptoms associated with allergy or a cold.

Usual Adult Dose for Cough

Immediate-release (IR): 5 mL orally every 4 to 6 hours as needed
Maximum dose: 20 mL in 24 hours

  • Each 5 mL of IR oral solution contains hydrocodone bitartrate 5 mg with chlorpheniramine maleate 4 mg

Extended-release (ER): One dose orally every 12 hours
Maximum dose: 2 doses in 24 hours
  • A dose equals 1 ER capsule or 5 mL ER suspension; each dose provides hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 8 mg chlorpheniramine maleate

Comments:
  • Oral solution and suspension must be measured with an accurate milliliter measuring device; do not use a household teaspoon.

Use: For the symptomatic relief of cough and upper respiratory symptoms associated with allergy or a cold.

Renal Dose Adjustments

Severe renal impairment: Use with caution

Liver Dose Adjustments

Severe hepatic impairment: Use with caution

Dose Adjustments

Elderly: Use with caution

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for all opioids intended for outpatient use. The new FDA Opioid Analgesic REMS is a designed to assist in communicating the serious risks of opioid pain medications to patients and health care professionals. It includes a medication guide and elements to assure safe use. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; RISK EVALUATION AND MITIGATION STRATEGY (REMS):

  • Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.
  • Opioid Analgesic REMS: To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, a REMS is required for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to complete a REMS-compliant education program; counsel patients and/or their caregivers, with every prescription on safe use, serious risks, storage, and disposal of these products; emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and consider other tools to improve patient, household, and community safety.

Safety and efficacy of the immediate-release oral solution have not been established in patients younger than 18 years.

The US FDA recommends against use of hydrocodone-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II (oral suspension/oral solution); Schedule III (oral capsules)

Dialysis

Data not available

Other Comments

Administration advice:

  • Shake suspension well prior to measuring
  • Measure oral solution and oral suspension with an accurate measuring device; a household teaspoon is not an accurate measuring device

General:
  • Leading pediatric and pulmonary health organizations recommend against symptomatic treatment of cough in pediatric patients due to lack of efficacy studies and the possibility of significant morbidity and mortality; benefit to risk should be carefully considered in pediatric patients with respiratory compromise.
  • The US FDA recommends against use of hydrocodone-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.

Monitoring:
  • Monitor for the development of addiction, abuse, or misuse

Patient advice:
  • Advise patients to store this drug safely out of the sight and reach of children; accidental use by a child is a medical emergency and can result in death.
  • Patients should understand the risks of life-threatening respiratory depression, and should be informed as to when this risk is greatest.
  • Women of child bearing potential should understand that prolonged opioid use during pregnancy can result in neonatal opioid withdrawal syndrome and that prompt recognition and treatment will be necessary; breastfeeding women should speak to their health care provider prior to using this drug.
  • Patients should be instructed in proper disposal.
  • Patients should not consume alcoholic beverages or take this drug with benzodiazepines or other CNS depressants; patients should avoid driving or operating machinery while taking this drug.
  • Patients should be instructed to read the US FDA-approved Medication Guide each time this drug is dispensed; they should understand the safe use, serious risks, and proper storage and disposal of this drug.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by